| HBS Case Collection
(Revised from original 2005 version)
Molecular Insight Pharmaceuticals, Inc.
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing. Should it continue its current strategy or change its approach? Includes color exhibits.
Keywords: Intellectual Property;
Health Care and Treatment;
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, March 2006. (Revised from original January 2005 version.)